

Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss

Jun 16, 2016

Improvements to OSS™ Orthopedic Salvage System Include New Implant Components and Redesigned Instrumentation to Offer Surgeons Greater Flexibility and Ease-of-Use during Complex Limb Salvage Procedures

WARSAW, Ind., June 16, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the global commercial launch of new enhancements to its OSS™ Orthopedic Salvage System, a comprehensive set of joint reconstruction prostheses designed to treat patients suffering from bone loss due to tumor resection, ligamentous deficiencies, orthopaedic trauma or patients who have undergone multiple knee and hip revision arthroplasties.



The Orthopedic Salvage System is the first and only limb salvage system utilizing OsseoTi®, a proprietary porous metal technology that is designed to mimic cancellous bone architecture¹ and promote biologic fixation through tissue ingrowth.² The Orthopedic Salvage System was first introduced in 2000 and has been successfully used in more than 15,000 patients to date worldwide.

The next-generation enhancements to the Orthopedic Salvage System include modern implant designs for the distal femur and diaphysis, small diameter Splined Stems and new implant components created with OsseoTi Porous Metal Technology:

- Updated Standard Size (3 cm and 5 cm) and Reduced Size (3 cm and 5 cm) distal femoral components featuring Vanguard® Patellofemoral Articulation
- Standard distal femoral component (3 cm) compatible to accept OsseoTi Femoral Sleeve Augments
- Tapered Diaphyseal Segments designed to accept Modular OsseoTi Diaphyseal Sleeve Augments
- Splined Stems to provide torsional stability through interference fit and splines

In addition, the Orthopedic Salvage System's surgical instrumentation platform now includes Universal Quick Connection, which offers surgeons greater ease-of-use and expandable implant provisionals to improve intraoperative speed and flexibility during certain complex limb salvage procedures.

"We're excited to further enhance the clinical utility of our revolutionary Orthopedic Salvage System with refreshed and new implant designs, improved surgical instrumentation as well as the utilization of OsseoTi Porous Metal technology to provide bone and soft tissue fixation often needed in limb salvage procedures," said Todd Davis, Vice President and General Manager of Zimmer Biomet's Knee business. "These upgrades reinforce Zimmer Biomet's commitment to partnering with surgeons by expanding and refining our product offering to improve the ease and efficiency of the surgical experience and improve procedure outcomes."

About OsseoTi Porous Metal Technology

Made of a cutting edge technology by printing the metal and porous structure together, OsseoTi Porous Metal creates a truly unified three-dimensional porous homogenous construct that is designed to mimic cancellous bone architecture¹ and promote biologic fixation through tissue ingrowth.² The Orthopedic Salvage System is the first limb salvage system in the U.S. to employ this technology.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

Zimmer Biomet has operations in more than 25 countries around the world and sells products in more than 100 countries. For more information, visit zimmerbiomet.com or follow Zimmer Biomet on Twitter at twitter.com/zimmerbiomet.

Zimmer Biomet does not practice medicine. The treating surgeon is responsible for determining the appropriate treatment, technique(s), and product(s) for each individual patient. For complete product information, including indications, contraindications, warnings, precautions, and potential adverse effects, see zimmerbiomet.com.

1. Biomet Test Report MT7196.
2. Gupta, G. OsseoTi Porous Metal for Enhanced Bone Integration: an Animal Study. Biomet Form No.BMET0718.1-GBL. 2014.

Legal Manufacturer

Biomet Orthopedics
P.O. Box 587
56 E. Bell Drive
Warsaw, Indiana 46581-0587
USA

www.zimmerbiomet.com

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

Logo - <http://photos.prnewswire.com/prnh/20150624/225371LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/zimmer-biomet-announces-enhancements-to-joint-reconstruction-portfolio-for-the-treatment-of-patients-with-significant-bone-loss-300286135.html>

SOURCE Zimmer Biomet Holdings, Inc.

News Provided by Acquire Media

[Close window](#) | [Back to top](#)